US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep ...

Cambridge, USA-based biotech Oak Hill Bio this morning announced plans to go public via a combination with RA Capital-backed ...

Shares of US biotech Forte Biosciences shot up nearly 40% to $76.40 in early trading, on the news of a takeover bid from ...

US clinical-stage US autoimmune drug developerKyverna Therapeutics (Nasdaq: KYTX) and ElevateBio, a contract development and manufacturing organization (CDMO), today announced a manufacturing ...

Three weeks after the UK launch of Danish pharma major Novo Nordisk’s (NOV: N) daily Wegovy Pill (semaglutide), weight health provider CheqUp says early demand indicates strong consumer interest in a ...

French pharma Ipsen (Euronext: IPN) has reported that its Phase III BOLD trial of Bylvay (odevixibat) in biliary atresia failed to meet its primary endpoint, dealing a setback to efforts to develop ...

US biotech Outlook Therapeutics revealed that the US Food and Drug Administration (FDA) has approved Lytenava ...

UK-based Novogene Europe, a multiomics research services partner, today announced that it has expanded its single-cell RNA ...

A commercial-stage Chinese biopharmaceutical company pursuing BTK and TYK2 inhibition across oncology and autoimmune disease, ...

A preclinical biotech company based in Wilmington, Delaware, focused on developing CAR‑T cell immunotherapies to treat severe allergic conditions. Founded in 2022, the company leverages novel CAR‑T ...

A biotech company spun-out from Aditum Bio and Leads Biolabs, with the aim to develop LBL-051, a first-in-class T-cell engager antibody for autoimmune diseases. The company was launched by Aditum Bio ...

A precision-oncology company developing small-molecule therapies to restore function of mutant forms of the tumor suppressor protein p53. The lead candidate is rezatapopt (PC14586), which is designed ...